Details for Patent: 3,674,870

Summary for Patent: 3,674,870

Title:	Phenyl benzoic acid compounds in compositions and methods for treating inflammation
Abstract:	The invention relates to a method of treating inflammation by administering substituted 5-(phenyl) benzoic acids, esters and non-toxic pharmaceutically accepted salts thereof to patients.
Inventor(s):	William V Ruyle, Lewis H Sarett, Alexander R Matzuk
Assignee:	Merck and Co Inc
Application Number:	US44868A
Patent Claim Types: see list of patent claims

Scope and US Patent 3,674,870 claims: method-of-treatment and pharmaceutical composition coverage for substituted benzoic acids

US Patent 3,674,870 claim language you provided centers on oral anti-inflammatory methods and pharmaceutical compositions built around a defined class of substituted benzoic acids. The claim set you pasted is strongest for (1) specific named actives (several fluorinated benzoic acids and their acetoxy/acetyl variants, plus one choline salt) and (2) a dose-ranging, oral administration regime. The practical landscape depends on whether competitors launch around different substitution patterns, non-oral routes, different dose regimens, or non-covered salts/derivatives, because the claims you provided are framed as method and composition claims tied to a formula-defined active ingredient set.

What does US Patent 3,674,870 claim protect in the United States?

Short answer: It protects US method-of-treatment claims for oral daily dosing of specified substituted benzoic acids for inflammation, plus pharmaceutical anti-inflammatory compositions containing those specified actives with a pharmaceutically acceptable carrier.

What claim 3 and claim 8 cover (method of treating inflammation)

From your text:

• Claim 3: “method of treating inflammation” by orally administering daily doses of about 2 mg to 70 mg per kg per day of a compound of a formula where R2 is hydrogen or lower alkanoyl or a pharmaceutically non-toxic salt of the acid.
• Claim 8: essentially the same treatment framing, also based on the same formula and the same oral daily dose range concept, again with R2 = hydrogen, lower alkanoyl, or pharmaceutically non-toxic salts.

Scope implications

• These are use claims (method-of-treatment) with both:
  1. Route limitation: “orally administering”
  2. Dose-range limitation: “daily doses…about 2 mg to 70 mg/kg body weight per day”
  3. Active-ingredient limitation: a formula class with R2 defined
  4. Indication limitation: “treating inflammation” (anti-inflammatory activity)

What claim 2 and claim 4–7 cover (specific actives within the formula)

Your excerpt includes nested dependent claims that identify specific compounds within the claim-3 formula framework:

• Claim 2: compound is 2-acetoxy-3-methyl-5-(4''-fluorophenyl) benzoic acid.
• Claim 4: compound is 2-hydroxy-5-(pentafluorophenyl) benzoic acid.
• Claim 5: compound is 2-hydroxy-5-(2''-fluorophenyl) benzoic acid.
• Claim 6: compound is 2-hydroxy-5-(3''-fluorophenyl) benzoic acid.
• Claim 7: compound is 2-hydroxy-5-(2'',4''-difluorophenyl) benzoic acid.

Scope implications

• These narrow the formula-based method claims to named substitution patterns. A product using any of these named actives at an infringing dose and route is within the dependent claim territory.

What claim 9–11 cover (more specific actives)

• Claim 9: 2-hydroxy-5-(4''-fluorophenyl) benzoic acid
• Claim 10: 2-acetoxy-5-(4''-fluorophenyl) benzoic acid
• Claim 11: choline salt of 2-hydroxy-5-(4''-fluorophenyl) benzoic acid

Scope implications

• Claim 11 gives explicit coverage to a specific salt form (choline), which can matter if competitors market alternate cations or salt forms. If the independent claim already covers “pharmaceutically non-toxic salt thereof,” then choline may be redundant for formula scope, but the dependent claim reduces freedom to argue non-coverage for that particular salt identity.

What claim 12–22 cover (pharmaceutical compositions)

Your excerpt includes:

• Claim 12: composition with “an effective amount of at least one member selected from” the compounds of the formula.
• Claim 14: similar composition claim with R2 defined as hydrogen or lower alkanoyl and pharmaceutically non-toxic salts, plus “pharmaceutically acceptable carrier.”
• Claims 13, 15–22: composition dependent claims that identify specific active ingredients and the choline salt again.

Scope implications

• These are composition claims that cover:
  • the formulation concept (API + pharmaceutically acceptable carrier)
  • the API selection (members from the formula set)
  • and in dependent form, several specific active ingredients

How broad are the “formula + R2” limits in claim 3/8 relative to the named compounds?

Short answer: Claim 3/8 are broad in the sense that they cover a defined formula class and a defined R2 substitution/salt set, but they still require both oral dosing and the “inflammation” treatment purpose. The dependent claims then lock the analysis into specific named actives.

R2 definition is a key pivot (hydrogen vs lower alkanoyl vs salt)

You provided: in claim 3/8, R2 is hydrogen or lower alkanoyl or a pharmaceutically non-toxic salt of the acid.

Practical interpretive effects for freedom-to-operate (FTO)

• “R2 = hydrogen” covers the acid (unsubstituted at that position) form within the formula class.
• “R2 = lower alkanoyl” covers acylated derivatives (your excerpt shows “acetoxy” and “acetyl” variants in dependent claims).
• “pharmaceutically non-toxic salt thereof” extends coverage to salts, subject to whether the salt qualifies as “pharmaceutically non-toxic” (a functional qualifier in the claim language you pasted).

Dependent claims show that fluorinated aryl substitution patterns are central

Your excerpt lists multiple aryl substitution patterns on the benzoic acid scaffold:

• pentafluorophenyl
• 2-, 3-, 4-fluorophenyl
• 2,4-difluorophenyl
• and multiple acetoxy vs hydroxy choices at specific positions, as reflected in the named compounds.

That pattern suggests the patent is not merely about “benzoic acids with one fluorine,” but about a specific substituted aromatic and benzoic acid relationship.

Which specific compounds are explicitly recited in US 3,674,870, and what are the corresponding claim types?

Short answer: The excerpted claims explicitly name a set of substituted hydroxy/acetoxy benzoic acids and one choline salt. Each appears in either a method-of-treatment claim chain or a composition claim chain.

Named actives tied to method claims (from your excerpt)

Named compound (active ingredient)	Appears in your pasted claims as	Claim numbers
2-acetoxy-3-methyl-5-(4''-fluorophenyl) benzoic acid	method dependent	2
2-hydroxy-5-(pentafluorophenyl) benzoic acid	method dependent	4
2-hydroxy-5-(2''-fluorophenyl) benzoic acid	method dependent	5
2-hydroxy-5-(3''-fluorophenyl) benzoic acid	method dependent	6
2-hydroxy-5-(2'',4''-difluorophenyl) benzoic acid	method dependent	7
2-hydroxy-5-(4''-fluorophenyl) benzoic acid	method dependent	9
2-acetoxy-5-(4''-fluorophenyl) benzoic acid	method dependent	10
choline salt of 2-hydroxy-5-(4''-fluorophenyl) benzoic acid	method dependent	11

Named actives tied to composition claims (from your excerpt)

Named compound (active ingredient)	Appears as	Claim numbers
2-acetoxy-3-methyl-5-(4''-fluorophenyl) benzoic acid	composition dependent	13
2-hydroxy-5-(pentafluorophenyl) benzoic acid	composition dependent	15
2-hydroxy-5-(2''-fluorophenyl) benzoic acid	composition dependent	16
2-hydroxy-5-(3''-fluorophenyl) benzoic acid	composition dependent	17
2-hydroxy-5-(2'',4''-difluorophenyl) benzoic acid	composition dependent	18
2-hydroxy-5-(4''-fluorophenyl) benzoic acid	composition dependent	20
2-acetoxy-5-(4''-fluorophenyl) benzoic acid	composition dependent	21
choline salt of 2-hydroxy-5-(4''-fluorophenyl) benzoic acid	composition dependent	22

What dosing and route limitations create infringement boundaries for oral generic or reformulation risks?

Short answer: The method claims are anchored on “daily doses” and “orally administering” within about 2 to 70 mg/kg/day, making route and dose a practical boundary for design-around. The composition claims lack those method dosing and route constraints, but still require the covered active ingredient set and a pharmaceutically acceptable carrier.

Method claim dosing risk surface

If a competitor targets the same active ingredient(s) listed in the dependent claims, then risk depends on whether its marketed regimen falls within:

• oral route, and
• daily dose about 2–70 mg/kg/day.

If an accused regimen is outside that range, that does not automatically eliminate risk, because claim interpretation can hinge on how “about” and mg/kg/day are construed, but it is a clear design axis.

Method claim indication framing: “treating inflammation”

A competitor marketed for a different medical purpose could try to reduce enforcement leverage, but the literal claim language is “method of treating inflammation.” If the product is used for inflammatory indications, enforcement risk remains tied to evidence of intended use and prescribing.

Which patent estate positions are most enforceable: method claims or composition claims?

Short answer: For litigation leverage, composition claims tend to be easier to prove at the product-identity level (API selection in the finished drug) while method claims require proof of the administration regime.

Composition claims (claim 12, 14, 13, 15–22) are “product identity” anchored

• They are less sensitive to real-world dosing and patient behavior.
• They require showing an infringing product contains an API that is within the formula-defined set (or the specifically named dependent compounds).

Method claims (claim 3, 8, plus dependent named actives) depend on regimen evidence

• They require evidence of:
  • oral administration
  • daily dosing range
  • and treating inflammation.

For enforcement, that often means more factual development than a composition-only theory.

What claims are likely to be most important for generic entry and Paragraph IV challenges?

Short answer: If the patent is listed in the FDA Orange Book for a specific NDA, the most common Paragraph IV “trigger” is whether a generic filing seeks approval for the same active ingredient(s) and dosage form, because composition claims map to product identity. Your excerpt does not provide Orange Book listing details, so the key analytic point is structural: these claims are the classic “formulation + dosing + use” mix that drives ANDA AND method-of-use arguments.

Generic entry risk scenarios implied by the claim text

1. Same active ingredient + oral dosing + inflammation use
   • Highest risk against both method and composition claims.
2. Same active ingredient but different route (not oral)
   • Composition claims may still be asserted; method claims may be harder.
3. Same active ingredient but dosing outside 2–70 mg/kg/day
   • Method claim risk reduced in practice; composition claim risk remains.
4. Different active ingredient (different fluorination pattern or different benzoic substitution)
   • Potentially reduces literal formula coverage, but depends on whether the new structure falls within the formula and R2 definitions.

What patent landscape signals exist from the claim language itself?

Short answer: The excerpt suggests a narrow but chemically specific estate around fluorinated substituted benzoic acids, with coverage spanning:

• hydroxy vs acetoxy/acetyl variants (via R2),
• multiple fluorinated aryl substitution patterns,
• at least one explicit salt form (choline).

That typically implies follow-on patents or related family members can exist that:

• broaden the substitution pattern,
• add additional salts,
• claim additional dosage forms or manufacturing methods,
• or claim additional indications.

Your pasted text does not include priority/filing data, related assignees, or other claims. Without those, the analysis is limited to claim-scope mechanics rather than a full family map.

How strong is the patent protection implied by these claims?

Short answer: Strength is medium-to-high at the points the claims most clearly cover: (1) specific named actives and (2) oral inflammation dosing within a quantified range. Strength is weaker against design-arounds that change route, dose range, or active-ingredient substitution so the formula and dependent claim recitations no longer match.

“Strength” drivers in your excerpt

• Named actives: multiple dependents list specific fluorinated hydroxy/acetoxy acids.
• Dose window: provides a concrete enforcement boundary for method claims.
• Salt coverage: “pharmaceutically non-toxic salt” plus explicit choline salt.

“Strength” inhibitors in your excerpt

• Without the full independent claim formula (the portion your text elides with “wherein the compound of the formula”), the exact structural boundary of the formula limitation cannot be fully assessed from the excerpt alone.
• If competitors use alternatives outside the specified structural set, the formula constraint can limit reach.

Key Takeaways

• US Patent 3,674,870 claim scope you provided covers oral daily dosing methods for inflammation and pharmaceutical anti-inflammatory compositions.
• The method claims are constrained by route (oral), dose range (~2 to 70 mg/kg/day), and active-ingredient formula/R2 limits.
• Dependent claims expressly enumerate multiple fluorinated hydroxy/acetoxy benzoic acids and one choline salt, which increases enforceability against products matching those actives.
• For freedom-to-operate, the most direct risk drivers are API identity (for composition claims) and route plus dosing regimen (for method claims).
• Design-around axes implied by the text are non-oral delivery, dose outside the stated mg/kg/day window, and chemical substitution outside the formula-defined set.

FAQs

1) Does US 3,674,870 cover both the free acid and salt forms of the substituted benzoic acids?

Yes for salts described as “pharmaceutically non-toxic salts” in the formula/R2 definition, and it also explicitly recites the choline salt for one specific active in dependent claim 11 and composition claim 22.

2) What is the practical importance of “orally administering” in the method claims?

It limits infringement for the method-of-treatment theory to oral administration, so non-oral routes can reduce or eliminate method-claim exposure while composition claims can still remain.

3) How does the mg/kg/day range affect generic switching and lifecycle management?

It creates a regimen design boundary for method claims. Composition claims do not rely on that dosing window, so formulation and API identity remain key.

4) Are fluorinated aryl substitution patterns central to coverage?

Yes. Your dependent claims explicitly list pentafluorophenyl, and 2-, 3-, 4-fluoro and 2,4-difluoro phenyl variants on the substituted benzoic acid scaffold.

5) If a competitor uses the same API but changes formulation excipients, is it still covered?

Your excerpt frames composition protection as “together with a pharmaceutically acceptable carrier.” That typically means excipients alone are unlikely to avoid the claim if the same covered API and qualifying carrier are present.

References

1. US Patent 3,674,870, “method of treating inflammation” and pharmaceutical composition claims (claim text provided in prompt).

Drugs Protected by US Patent 3,674,870

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate